Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT03943082 Terminated - Malignant Neoplasm Clinical Trials

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

Start date: April 8, 2019
Phase: N/A
Study type: Interventional

This trial studies how well a follow-up phone call regarding financial reimbursement program (FRP) works in improving cancer patients' access to therapeutic cancer clinical trials. Follow-up phone call intervention regarding FRP may improve recruitment of cancer patients to cancer therapeutic clinical trials.

NCT ID: NCT03926143 Terminated - Solid Tumors Clinical Trials

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

NCT ID: NCT03894540 Terminated - Solid Tumor Clinical Trials

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Start date: March 22, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).

NCT ID: NCT03878524 Terminated - Anemia Clinical Trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Start date: April 1, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.

NCT ID: NCT03871855 Terminated - Clinical trials for Advanced Solid Tumor

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Start date: April 28, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.

NCT ID: NCT03854227 Terminated - Clinical trials for Advanced Solid Tumors

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Start date: March 14, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

NCT ID: NCT03839940 Terminated - Malignant Neoplasm Clinical Trials

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

MIST
Start date: February 15, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.

NCT ID: NCT03834220 Terminated - Solid Tumor Clinical Trials

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Start date: March 22, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

NCT ID: NCT03822117 Terminated - Clinical trials for Solid Tumor Malignancy

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Start date: October 17, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

NCT ID: NCT03809130 Terminated - Malignant Neoplasm Clinical Trials

Effectiveness of an Online Intervention Targeting Cancer-related Fatigue

Start date: December 10, 2018
Phase: N/A
Study type: Interventional

This trial studies how well Untire application intervention works in reducing cancer-related fatigue in cancer patients and survivors.The Untire application focuses on themes that have been identified as causing or contributing to cancer-related fatigue. It may provide information and tips to improve lifestyle, give exercises for body and mind to increase energy levels, offer weekly reports to measure progress, and offer access to an online support community.